Access Anti-Müllerian Hormone (AMH) Assay Voted Best New Clinical Product of 2014
BREA, Calif. — (August 31, 2015) — Beckman Coulter Diagnostics’ automated Access Anti-Müllerian Hormone (AMH) assay* was recently selected as the Best New Clinical Laboratory Product of 2014 for the 2015 Scientists’ Choice Award by members of SelectScience®. The award was presented this summer at this year’s American Association for Clinical Chemistry (AACC) Clinical Lab Expo in Atlanta, GA.
The automated Access Anti-Müllerian Hormone (AMH) assay* is Beckman Coulter’s latest innovation in women’s health testing and further advances the company’s rich 15-year history and experience in supporting global fertility assessment and treatment.
The Access AMH assay brings automation and convenience to Beckman Coulter’s established AMH tests, which include the AMH Gen II ELISA assay and the Immunotech EIA AMH/MIS assay. The company’s AMH assays have become the industry standard since the first commercial AMH assay was introduced in 1999, as evidenced by more than 2,000 scientific articles and publications.
“Beckman Coulter is humbled and thrilled to receive the Scientists’ Choice Award from SelectScience,” said John Blackwood, senior vice president of Beckman Coulter’s Chemistry/Immunoassay business unit. “Beckman Coulter has been pioneering the AMH immunoassay space since 1999. Last year we launched the automated assay and we are honored that its value is being acknowledged by clinicians.”
This year’s final nominees included Abbott, Alere, Randox, Roche and Siemens. Being among an elite group of competitors further demonstrates how Beckman Coulter offers solutions that continue to move healthcare forward.To view a video of the award presentation click here.